8 recherche sur le mot-clé 'Antipsychotics'

Antipsychotic Use and Metabolic Monitoring in Individuals with Developmental Disabilities Served in a Medicaid Medical Home / Lisa M. RUIZ in Journal of Autism and Developmental Disorders, 46-6 (June 2016)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 46-6 (June 2016) . - p.1887-1894 Titre : Antipsychotic Use and Metabolic Monitoring in Individuals with Developmental Disabilities Served in a Medicaid Medical Home Type de document : texte imprimé Auteurs : Lisa M. RUIZ, Auteur ; Mackenzie DAMRON, Auteur ; Kyle B. JONES, Auteur ; Dean WEEDON, Auteur ; Paul S. CARBONE, Auteur ; Amanda V. BAKIAN, Auteur ; Deborah A. BILDER, Auteur Article en page(s) : p.1887-1894 Langues : Anglais (eng) Mots-clés : Antipsychotics  Autism spectrum disorder  Intellectual disability  Medical home Index. décimale : PER Périodiques Résumé : This study describes antipsychotic use and metabolic monitoring rates among individuals with developmental disabilities enrolled in a subspecialty medical home (N = 826). Four hundred ninety-nine participants (60.4 %) were taking antipsychotics, which was associated with male gender (p = 0.01), intellectual disability with and without autism spectrum disorder (p = 0.001 and p = 0.04, respectively), and inversely associated with the youngest and oldest age categories (p = 0.001 and p = 0.04, respectively). Among those taking antipsychotics, annual metabolic monitoring rates ranged from 89 % (lipids) to 99 % (weight). Age was positively associated with glucose (p < 0.001) and lipid monitoring (p < 0.001). Adult participants with dyslipidemia (p < 0.01), prediabetes/diabetes (p = 0.04), and hypertension (p = 0.02) were significantly more likely to obtain lipid monitoring. These values exceeded previously reported rates suggesting the importance of an integrated care model. En ligne : http://dx.doi.org/10.1007/s10803-016-2712-x Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=288 [article] Antipsychotic Use and Metabolic Monitoring in Individuals with Developmental Disabilities Served in a Medicaid Medical Home [texte imprimé] / Lisa M. RUIZ, Auteur ; Mackenzie DAMRON, Auteur ; Kyle B. JONES, Auteur ; Dean WEEDON, Auteur ; Paul S. CARBONE, Auteur ; Amanda V. BAKIAN, Auteur ; Deborah A. BILDER, Auteur . - p.1887-1894. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 46-6 (June 2016) . - p.1887-1894 Mots-clés : Antipsychotics  Autism spectrum disorder  Intellectual disability  Medical home Index. décimale : PER Périodiques Résumé : This study describes antipsychotic use and metabolic monitoring rates among individuals with developmental disabilities enrolled in a subspecialty medical home (N = 826). Four hundred ninety-nine participants (60.4 %) were taking antipsychotics, which was associated with male gender (p = 0.01), intellectual disability with and without autism spectrum disorder (p = 0.001 and p = 0.04, respectively), and inversely associated with the youngest and oldest age categories (p = 0.001 and p = 0.04, respectively). Among those taking antipsychotics, annual metabolic monitoring rates ranged from 89 % (lipids) to 99 % (weight). Age was positively associated with glucose (p < 0.001) and lipid monitoring (p < 0.001). Adult participants with dyslipidemia (p < 0.01), prediabetes/diabetes (p = 0.04), and hypertension (p = 0.02) were significantly more likely to obtain lipid monitoring. These values exceeded previously reported rates suggesting the importance of an integrated care model. En ligne : http://dx.doi.org/10.1007/s10803-016-2712-x Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=288

Characterization of Medication Use in a Multicenter Sample of Pediatric Inpatients with Autism Spectrum Disorder / Logan K. WINK in Journal of Autism and Developmental Disorders, 48-11 (November 2018)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 48-11 (November 2018) . - p.3711-3719 Titre : Characterization of Medication Use in a Multicenter Sample of Pediatric Inpatients with Autism Spectrum Disorder Type de document : texte imprimé Auteurs : Logan K. WINK, Auteur ; Ernest V. PEDAPATI, Auteur ; Ryan ADAMS, Auteur ; Craig ERICKSON, Auteur ; Kahsi A. PEDERSEN, Auteur ; Eric M. MORROW, Auteur ; Desmond KAPLAN, Auteur ; Matthew SIEGEL, Auteur Article en page(s) : p.3711-3719 Langues : Anglais (eng) Mots-clés : Antipsychotics  Autism  Autism Spectrum Disorder  Medication  Psychiatric hospitalization Index. décimale : PER Périodiques Résumé : Nearly 11% of youth with Autism Spectrum Disorder (ASD) undergo psychiatric hospitalization, and 65% are treated with psychotropic medication. Here we characterize psychotropic medication usage in subjects enrolled in the Autism Inpatient Collection. Participant psychotropic medication usage rates topped 90% at admission and discharge, though there was a decline at 2-month follow-up. Antipsychotics, ADHD medications, and sleep aids were the most commonly reported classes of medications. The impact of age, gender, and non-verbal IQ on medication usage rates was minimal, though age and IQ may play a role in prescribing practices. Future work is indicated to explore medication usage trends, the impact of clinical factors on medication use rates, and the safety of psychotropic medications in youth with ASD. En ligne : http://dx.doi.org/10.1007/s10803-017-3153-x Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=370 [article] Characterization of Medication Use in a Multicenter Sample of Pediatric Inpatients with Autism Spectrum Disorder [texte imprimé] / Logan K. WINK, Auteur ; Ernest V. PEDAPATI, Auteur ; Ryan ADAMS, Auteur ; Craig ERICKSON, Auteur ; Kahsi A. PEDERSEN, Auteur ; Eric M. MORROW, Auteur ; Desmond KAPLAN, Auteur ; Matthew SIEGEL, Auteur . - p.3711-3719. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 48-11 (November 2018) . - p.3711-3719 Mots-clés : Antipsychotics  Autism  Autism Spectrum Disorder  Medication  Psychiatric hospitalization Index. décimale : PER Périodiques Résumé : Nearly 11% of youth with Autism Spectrum Disorder (ASD) undergo psychiatric hospitalization, and 65% are treated with psychotropic medication. Here we characterize psychotropic medication usage in subjects enrolled in the Autism Inpatient Collection. Participant psychotropic medication usage rates topped 90% at admission and discharge, though there was a decline at 2-month follow-up. Antipsychotics, ADHD medications, and sleep aids were the most commonly reported classes of medications. The impact of age, gender, and non-verbal IQ on medication usage rates was minimal, though age and IQ may play a role in prescribing practices. Future work is indicated to explore medication usage trends, the impact of clinical factors on medication use rates, and the safety of psychotropic medications in youth with ASD. En ligne : http://dx.doi.org/10.1007/s10803-017-3153-x Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=370

Psychotropic Medication Use among Insured Children with Autism Spectrum Disorder / Jeanne M. MADDEN in Journal of Autism and Developmental Disorders, 47-1 (January 2017)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 47-1 (January 2017) . - p.144-154 Titre : Psychotropic Medication Use among Insured Children with Autism Spectrum Disorder Type de document : texte imprimé Auteurs : Jeanne M. MADDEN, Auteur ; Matthew D. LAKOMA, Auteur ; Frances L. LYNCH, Auteur ; Donna RUSINAK, Auteur ; Ashli A. OWEN-SMITH, Auteur ; Karen J. COLEMAN, Auteur ; Virginia P. QUINN, Auteur ; Vincent M. YAU, Auteur ; Yinge QIAN, Auteur ; Lisa A. CROEN, Auteur Article en page(s) : p.144-154 Langues : Anglais (eng) Mots-clés : Autism spectrum disorder  Medications  Antipsychotics  Comorbidities  Epidemiological studies Index. décimale : PER Périodiques Résumé : This study examined psychotropic medication use among 7901 children aged 1–17 with autism spectrum disorder (ASD) in five health systems, comparing to matched cohorts with no ASD. Nearly half (48.5 %) of children with ASD received psychotropics in the year observed; the most common classes were stimulants, alpha-agonists, or atomoxetine (30.2 %), antipsychotics (20.5 %), and antidepressants (17.8 %). Psychotropic treatment was far more prevalent among children with ASD, as compared to children with no ASD (7.7 % overall), even within strata defined by the presence or absence of other psychiatric diagnoses. The widespread use of psychotropics we observed, particularly given weak evidence supporting the effectiveness of these medications for most children with ASD, highlights challenges in ASD treatment and the need for greater investment in its evaluation. En ligne : http://dx.doi.org/10.1007/s10803-016-2946-7 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=298 [article] Psychotropic Medication Use among Insured Children with Autism Spectrum Disorder [texte imprimé] / Jeanne M. MADDEN, Auteur ; Matthew D. LAKOMA, Auteur ; Frances L. LYNCH, Auteur ; Donna RUSINAK, Auteur ; Ashli A. OWEN-SMITH, Auteur ; Karen J. COLEMAN, Auteur ; Virginia P. QUINN, Auteur ; Vincent M. YAU, Auteur ; Yinge QIAN, Auteur ; Lisa A. CROEN, Auteur . - p.144-154. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 47-1 (January 2017) . - p.144-154 Mots-clés : Autism spectrum disorder  Medications  Antipsychotics  Comorbidities  Epidemiological studies Index. décimale : PER Périodiques Résumé : This study examined psychotropic medication use among 7901 children aged 1–17 with autism spectrum disorder (ASD) in five health systems, comparing to matched cohorts with no ASD. Nearly half (48.5 %) of children with ASD received psychotropics in the year observed; the most common classes were stimulants, alpha-agonists, or atomoxetine (30.2 %), antipsychotics (20.5 %), and antidepressants (17.8 %). Psychotropic treatment was far more prevalent among children with ASD, as compared to children with no ASD (7.7 % overall), even within strata defined by the presence or absence of other psychiatric diagnoses. The widespread use of psychotropics we observed, particularly given weak evidence supporting the effectiveness of these medications for most children with ASD, highlights challenges in ASD treatment and the need for greater investment in its evaluation. En ligne : http://dx.doi.org/10.1007/s10803-016-2946-7 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=298

Relationship Between Antipsychotic Use and Cholesterol Levels in a Retrospective Chart Review of an Adult Autism Clinic Patient Population / Alisha J. STEIGERWALD ; Malori CHRISMAN ; Tanvi YADLAPALLI ; David Q. BEVERSDORF in Autism Research, 18-6 (June 2025)  

Public ISBD [article]  inAutism Research > 18-6 (June 2025) . - p.1187-1194 Titre : Relationship Between Antipsychotic Use and Cholesterol Levels in a Retrospective Chart Review of an Adult Autism Clinic Patient Population Type de document : texte imprimé Auteurs : Alisha J. STEIGERWALD, Auteur ; Malori CHRISMAN, Auteur ; Tanvi YADLAPALLI, Auteur ; David Q. BEVERSDORF, Auteur Article en page(s) : p.1187-1194 Langues : Anglais (eng) Mots-clés : antipsychotics  autism  cholesterol  GI comorbidities  metabolic comorbidities Index. décimale : PER Périodiques Résumé : ABSTRACT Individuals with autism spectrum disorder (ASD) experience a high prevalence of metabolic and gastrointestinal (GI) comorbidities. Antipsychotics are commonly prescribed for adults with ASD. Our study investigated the effect of antipsychotic medication on metabolic and GI comorbidities, as well as effects across age, in an adult ASD population. We retrospectively analyzed 279 charts from patients with ASD, ages 16 62 (mean 27.97, SD 8.89, 18.3% female). Data abstracted included demographic information, medications taken, GI and metabolic comorbidities, and recent values for body mass index (BMI), triglycerides, and total cholesterol. Participants were separated into two groups based on antipsychotic use. Between-group differences were calculated for the prevalence of GI comorbidities and mean values for BMI, triglycerides, and total cholesterol. Lastly, binary correlations were calculated for age and total cholesterol as well as triglycerides, and age and BMI. No significant difference was found between the prevalence of GI comorbidities for the two groups. For metabolic factors, no significant difference was found in the mean BMI, triglycerides, or total cholesterol. Binary correlation analysis also revealed no significant correlation between age and BMI or triglycerides for patients in either group. A significant correlation was found between age and total cholesterol for patients both taking and not taking antipsychotics. Despite approximately one in three patients in this study taking an antipsychotic medication, no significant differences in GI or metabolic comorbidities were found. However, cholesterol increased with age regardless of the presence or absence of antipsychotics. Future research is needed to better understand the long-term effects of antipsychotics on adults with ASD and metabolic monitoring in those not on antipsychotics. En ligne : https://doi.org/10.1002/aur.70047 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=558 [article] Relationship Between Antipsychotic Use and Cholesterol Levels in a Retrospective Chart Review of an Adult Autism Clinic Patient Population [texte imprimé] / Alisha J. STEIGERWALD, Auteur ; Malori CHRISMAN, Auteur ; Tanvi YADLAPALLI, Auteur ; David Q. BEVERSDORF, Auteur . - p.1187-1194. Langues : Anglais (eng) in Autism Research > 18-6 (June 2025) . - p.1187-1194 Mots-clés : antipsychotics  autism  cholesterol  GI comorbidities  metabolic comorbidities Index. décimale : PER Périodiques Résumé : ABSTRACT Individuals with autism spectrum disorder (ASD) experience a high prevalence of metabolic and gastrointestinal (GI) comorbidities. Antipsychotics are commonly prescribed for adults with ASD. Our study investigated the effect of antipsychotic medication on metabolic and GI comorbidities, as well as effects across age, in an adult ASD population. We retrospectively analyzed 279 charts from patients with ASD, ages 16 62 (mean 27.97, SD 8.89, 18.3% female). Data abstracted included demographic information, medications taken, GI and metabolic comorbidities, and recent values for body mass index (BMI), triglycerides, and total cholesterol. Participants were separated into two groups based on antipsychotic use. Between-group differences were calculated for the prevalence of GI comorbidities and mean values for BMI, triglycerides, and total cholesterol. Lastly, binary correlations were calculated for age and total cholesterol as well as triglycerides, and age and BMI. No significant difference was found between the prevalence of GI comorbidities for the two groups. For metabolic factors, no significant difference was found in the mean BMI, triglycerides, or total cholesterol. Binary correlation analysis also revealed no significant correlation between age and BMI or triglycerides for patients in either group. A significant correlation was found between age and total cholesterol for patients both taking and not taking antipsychotics. Despite approximately one in three patients in this study taking an antipsychotic medication, no significant differences in GI or metabolic comorbidities were found. However, cholesterol increased with age regardless of the presence or absence of antipsychotics. Future research is needed to better understand the long-term effects of antipsychotics on adults with ASD and metabolic monitoring in those not on antipsychotics. En ligne : https://doi.org/10.1002/aur.70047 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=558

Risperidone versus aripiprazole fracture risk in children and adolescents with autism spectrum disorders / Richard HOUGHTON in Autism Research, 14-8 (August 2021)  

Public ISBD [article]  inAutism Research > 14-8 (August 2021) . - p.1800-1814 Titre : Risperidone versus aripiprazole fracture risk in children and adolescents with autism spectrum disorders Type de document : texte imprimé Auteurs : Richard HOUGHTON, Auteur ; Joop VAN DEN BERGH, Auteur ; J. Kiely LAW, Auteur ; Yutong LIU, Auteur ; Frank DE VRIES, Auteur Article en page(s) : p.1800-1814 Langues : Anglais (eng) Mots-clés : Adolescent  Antipsychotic Agents/adverse effects  Aripiprazole/adverse effects  Autism Spectrum Disorder/complications/drug therapy/epidemiology  Child  Cohort Studies  Female  Fractures, Bone/drug therapy/epidemiology  Humans  Male  Retrospective Studies  Risperidone/adverse effects  United States/epidemiology  antipsychotics  aripiprazole  autism spectrum disorder  fractures  risperidone Index. décimale : PER Périodiques Résumé : Risperidone and aripiprazole, commonly used antipsychotics in children with autism spectrum disorder (ASD), have previously been associated with elevated fracture risk in other populations. The aim of this study was to evaluate and compare the risk of fracture among children with ASD using risperidone or aripiprazole. This was a retrospective, propensity-score matched cohort study, set between January 2013 and December 2018. We used the MarketScan Medicaid insurance data, which covers multiple states of the United States. We included ASD children aged 2-18 years, who were new users of aripiprazole or risperidone and with no prior history of antipsychotic use or fractures. The main exposure was the continued use of aripiprazole or risperidone. The incidence rates of any fracture during follow-up were evaluated, and the risk between aripiprazole and risperidone was compared via Cox-proportional hazard models. Results were stratified by age, sex, duration of exposure and fracture site. In total, 3312 patients (78% male; mean [SD] age 11.0 [3.7] years) were identified for each cohort. Over the full duration of follow-up, fracture incidence rates per 1000 patient-years were 23.2 for risperidone and 38.4 for aripiprazole (hazard ratio and 95% confidence interval: 0.60 [0.44-0.83]). Risks were similar between cohorts throughout the first 180 days on treatment, but significantly higher in the aripiprazole group thereafter. Extremity fractures drove most of the increased risk, with the biggest differences in lower leg and ankle fractures. Differences widened for children aged 10 years or younger (HR [95% CI]: 0.47 [0.30-0.74]). In conclusion, compared to aripiprazole, risperidone was associated with 40% lower risk of fracture. Further analysis on the mechanism and long-term bone health of antipsychotic-treated children with ASD is warranted. LAY SUMMARY: We compared the risk of bone fractures among 6624 children with autism spectrum disorder (ASD), half of whom used risperidone and half of whom used aripiprazole. Taking other factors into account, risks were similar between the two groups throughout the first 180 days on treatment, but significantly higher in the aripiprazole group thereafter. The biggest differences were in lower leg and ankle fractures. Overall, compared with aripiprazole, risperidone was associated with 40% lower risk of fracture. En ligne : http://dx.doi.org/10.1002/aur.2541 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=449 [article] Risperidone versus aripiprazole fracture risk in children and adolescents with autism spectrum disorders [texte imprimé] / Richard HOUGHTON, Auteur ; Joop VAN DEN BERGH, Auteur ; J. Kiely LAW, Auteur ; Yutong LIU, Auteur ; Frank DE VRIES, Auteur . - p.1800-1814. Langues : Anglais (eng) in Autism Research > 14-8 (August 2021) . - p.1800-1814 Mots-clés : Adolescent  Antipsychotic Agents/adverse effects  Aripiprazole/adverse effects  Autism Spectrum Disorder/complications/drug therapy/epidemiology  Child  Cohort Studies  Female  Fractures, Bone/drug therapy/epidemiology  Humans  Male  Retrospective Studies  Risperidone/adverse effects  United States/epidemiology  antipsychotics  aripiprazole  autism spectrum disorder  fractures  risperidone Index. décimale : PER Périodiques Résumé : Risperidone and aripiprazole, commonly used antipsychotics in children with autism spectrum disorder (ASD), have previously been associated with elevated fracture risk in other populations. The aim of this study was to evaluate and compare the risk of fracture among children with ASD using risperidone or aripiprazole. This was a retrospective, propensity-score matched cohort study, set between January 2013 and December 2018. We used the MarketScan Medicaid insurance data, which covers multiple states of the United States. We included ASD children aged 2-18 years, who were new users of aripiprazole or risperidone and with no prior history of antipsychotic use or fractures. The main exposure was the continued use of aripiprazole or risperidone. The incidence rates of any fracture during follow-up were evaluated, and the risk between aripiprazole and risperidone was compared via Cox-proportional hazard models. Results were stratified by age, sex, duration of exposure and fracture site. In total, 3312 patients (78% male; mean [SD] age 11.0 [3.7] years) were identified for each cohort. Over the full duration of follow-up, fracture incidence rates per 1000 patient-years were 23.2 for risperidone and 38.4 for aripiprazole (hazard ratio and 95% confidence interval: 0.60 [0.44-0.83]). Risks were similar between cohorts throughout the first 180 days on treatment, but significantly higher in the aripiprazole group thereafter. Extremity fractures drove most of the increased risk, with the biggest differences in lower leg and ankle fractures. Differences widened for children aged 10 years or younger (HR [95% CI]: 0.47 [0.30-0.74]). In conclusion, compared to aripiprazole, risperidone was associated with 40% lower risk of fracture. Further analysis on the mechanism and long-term bone health of antipsychotic-treated children with ASD is warranted. LAY SUMMARY: We compared the risk of bone fractures among 6624 children with autism spectrum disorder (ASD), half of whom used risperidone and half of whom used aripiprazole. Taking other factors into account, risks were similar between the two groups throughout the first 180 days on treatment, but significantly higher in the aripiprazole group thereafter. The biggest differences were in lower leg and ankle fractures. Overall, compared with aripiprazole, risperidone was associated with 40% lower risk of fracture. En ligne : http://dx.doi.org/10.1002/aur.2541 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=449

Practitioner Review: Pharmacological treatment of attention-deficit/hyperactivity disorder symptoms in children and youth with autism spectrum disorder: a systematic review and meta-analysis / Rebecca RODRIGUES in Journal of Child Psychology and Psychiatry, 62-6 (June 2021)  

Permalink

Practitioner Review: Treatment of Schizophrenia in Childhood and Adolescence / Andrew F. CLARK in Journal of Child Psychology and Psychiatry, 39-8 (November 1998)

Permalink

A preliminary study of pharmacogenetic biomarkers for individuals with autism and gastrointestinal dysfunction / A.E. SHINDLER in Research in Autism Spectrum Disorders, 71 (March 2020)  

Permalink